>>NCT01255163
- INCLUSION.
 - Age > 60.
 - Clinical Dementia Rating ( global CDR ) of 0.5 or 1. Memory box score must be at least 0.5.
 - Mini Mental Status Exam ( MMSE ) > 20.
 - Clinical diagnosis of ( amnestic or mixed ) MCI or early AD, at the judgment of the Principal Investigator. Memory deficit on neuropsychological or clinical testing.
 - Hamilton Depression Scale score of less than or equal to 12 on the 17 -item scale.
 - CSF A beta 42 < 192 (+- 10%) pg/ml ( given an intra-subject laboratory variability ~ 10%).
 - Medications stable for at least 4 weeks prior to screening. In particular :.
 - Participants may take stable doses of antidepressants, chronic anxiolytics or sedative hypnotics, at the discretion of the Principal Investigator, if started at least 4 weeks prior to screening.
 - Cholinesterase inhibitors and/or memantine are allowable, if started at least 4 weeks prior to screening.
 - Participants will not be asked to discontinue medications without permission from their physician.
 - Fluency in English.
 - At the time of enrollment, participants must have the ability to provide informed consent and make health care decisions.
 - An informant or caregiver who has frequent contact with the participant ( e.g. an average of 10 hours per week or more ) must be appointed to serve as Durable Power of Attorney ( DPA ) for research and medical care at NIA, accompany the participant to clinic visits and provide historical information regarding the participant s cognitive status and assist participants with/administer injections of the investigational medication.
 - Good general health with no additional disease states that could interfere with the study, at the discretion of the Principal Investigator.
 - Willing and able to complete all baseline assessments ( including ApoE genotyping ).
 - Willing to have an initial Lumbar Puncture and provide CSF at protocol specified time points.
 - Willing and able to participate in a 18 -month protocol.
 EXCLUSION.
 - Other significant neurological disease of the Central Nervous System ( such as Parkinson s disease, Multi-infarct Dementia, Frontotemporal Dementia, Huntington s disease, Normal Pressure Hydrocephalus, brain tumor, Progressive Supranuclear Palsy, Epilepsy, Subdural Hematoma or Multiple Sclerosis ).
 - A history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
 - Significant neuroimaging abnormalities, previously known or discovered on the initial MRI scan, including evidence of infection, infarction (> 3 mm in size ), brain tumors ( other than small meningiomas or other benign lesions ) or other focal lesions, multiple lacunes or lacunes in a critical memory structure or severe confluent microvascular disease ( but not mild white matter changes, which are frequent with aging ).
 - Positive RPR or HIV.
 - Coagulopathy or anti-coagulant therapy ( such as coumadin ) increasing the risk for LP resulting in PT/PTT and INR within 1.5 standard deviation over the upper normal limit.
 - Investigators unable to obtain CSF, at the clinical judgment of the investigator performing the procedure ( failure of Lumbar Puncture after a limited number of unsuccessful attempts ).
 - History of significant psychiatric disease, at the discretion of the Principal Investigator. Participants who develop psychiatric conditions necessitating treatment after their enrollment will not be dropped from the study. The high incidence of late-onset depression among individuals with MCI and AD requires that certain participants with depression, at the discretion of the Principal Investigator, should be included in the cohort to maintain the ecological validity of the results.
 - Significant history of alcoholism or substance abuse, at the discretion of the Principal Investigator.
 - Known diagnosis of diabetes at the time of enrollment or new diagnosis of diabetes based on the findings of elevated fasting blood glucose (= or > 126 mg/dl ) and/or the oral glucose tolerance test at screening (> 200 mg/dl at two hours ).
 - Severe renal impairment ( creatinine clearance < 30 ml/min ) or end-stage renal disease. Individuals with moderate renal impairment ( creatinine clearance 30 to 50 ml/min ) may be enrolled in the study but their BUN and Creatinine will be followed closely. All participants, in whom BUN or creatinine increased after switching from 5 microgram SC bid to 10 microgram SC bid ( but not with 5 microgram SC bid ), will be switched back to 5 microgram SC bid. If the BUN/Creatinine elevation persists one week later with the lower dose, the participant will be withdrawn from the study.
 - Current or previous treatment with Exendin- 4.
 - History of pancreatitis, active upper GI, hepatic or gallbladder disease.
 - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
 - History of repeated hypoglycemia.
 - Body mass index ( BMI ) < 20 on enrollment ( given the expected weight loss caused by Exendin- 4 and dementia ). In the BLSA, participants with age > 65 had a mean BMI of 25.8 with SD of 3.9 Exendin- 4 has been shown to cause an average 5.3 kg weight loss, with 95% CI : 6 to 4.5 kg.
 - Allergy to Exendin- 4 or to substances in the injection pen ( metacresol, mannitol, glacial acetic acid, sodium acetate trihydrate, water for injection ).
 - Participation in other studies of investigational treatments for Alzheimer's disease.
 - Refusal to consent to the initial Lumbar Puncture and ApoE genotyping.

>>NCT00066157
Inclusion Criteria :.
 - Postmenopausal women with Alzheimer's disease and without other dementias ( diagnosed by study staff or from an outside clinic ).
 - Mini Mental State Examination score greater than 15 - 30.
 Exclusion Criteria :.
 - History of cancer of reproductive tissues.
 - History of deep vein thrombosis or blot clots.
 - Diabetes.
 - Heart disease or stroke.
 - Liver problems including hepatitis.
 - Severe vision or hearing problems.
 - Tobacco use.
 - Lack of an adequate caregiver.
 - inability to perform psychometric testing.

>>NCT01231971
Inclusion Criteria :.
 Participants will be classified as either normal controls, SMC, EMCI, LMCI or AD participants. General Inclusion Criteria will apply to all groups, with specific criteria for each group as described below :.
 General ( applies to each category ):.
 - Geriatric Depression Scale less than 6.
 - Age between *55 - 90 ( inclusive ). *For normal controls and SMC participants, age must be between 65 - 90.
 - Study partner is available who has frequent contact with the participant ( e.g. an average of 10 hours per week or more ) and can accompany the participant to all clinic visits for the duration of the protocol.
 - Visual and auditory acuity adequate for neuropsychological testing.
 - Good general health with no diseases expected to interfere with the study.
 - Participant is not pregnant, lactating or of childbearing potential ( i.e. women must be two years post-menopausal or surgically sterile ).
 - Willing and able to participate in a longitudinal imaging study.
 - Hachinski less than or equal to 4.
 - Completed six grades of education or has a good work history ( sufficient to exclude mental retardation ).
 - Must speak English or Spanish fluently.
 - Willing to undergo repeated MRIs ( 3Tesla ) and at least two PET scans ( one FDG and one Amyloid imaging ) and no medical contraindications to MRI.
 - Agrees to collection of blood for Genome Wide Association Studies ( GWAS ), APOE testing and DNA and RNA banking.
 - Agrees to collection of blood for biomarker testing.
 - Agrees to at least one lumbar puncture for the collection of CSF.
 Specific Inclusion Criteria for normal controls :.
 - Participant must be free of memory complaints, verified by a study partner.
 - Normal memory function score on Wechsler Memory Scale ( adjusted for education ).
 - Mini-Mental State Exam ( MMSE ) score between 24 and 30 ( inclusive ).
 - Clinical Dementia Rating ( CDR ) = 0; Memory Box score must be 0.
 - Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living.
 - Stability of Permitted Medications for 4 weeks. In particular, participants may take :.
 - Antidepressants lacking significant anticholinergic side effects.
 - Estrogen replacement therapy is permissible.
 - Gingko biloba is permissible but discouraged.
 - Washout from psychoactive medication ( e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.
 Specific Inclusion Criteria for SMC participants :.
 - Subjects that are "self-referrals" that have a significant subjective memory concern.
 - Significant memory concern confirmed by a Cognitive Change Index score of more than or equal to 16.
 - Normal memory function score on Wechsler Memory Scale ( adjusted for education ).
 - Mini-Mental State Exam ( MMSE ) score between 24 and 30 ( inclusive ).
 - Clinical Dementia Rating ( CDR ) = 0; Memory Box score must be 0.
 - Cognitively normal, based on the absence of significant memory impairment in cognitive function or activities of daily living.
 - Stability of Permitted Medications for 4 weeks. In particular, subjects may take :.
 - Antidepressants lacking significant anticholinergic side effects.
 - Estrogen replacement therapy is permissible.
 - Gingko biloba is permissible but discouraged.
 - Washout from psychoactive medication ( e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.
 Specific Inclusion Criteria for EMCI and LMCI participants :.
 - Participant must have a subjective memory concern as reported by participant, study partner or clinician.
 - Abnormal memory function score on Wechsler Memory Scale ( adjusted for education ).
 - Mini-Mental State Exam ( MMSE ) score between 24 and 30 ( inclusive ).
 - Clinical Dementia Rating ( CDR ) = 0.5; Memory Box score must be at least 0.5.
 - General cognition and functional performance sufficiently preserved such that a diagnosis of AD cannot be made by the site physician at the time of the screening visit.
 - Stability of Permitted Medications for 4 weeks. In particular, participants may take :.
 - Antidepressants lacking significant anticholinergic side effects.
 - Estrogen replacement therapy.
 - Gingko biloba is permissible but discouraged.
 - Washout from psychoactive medication ( e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.
 - Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screening.
 Specific Inclusion Criteria for AD participants :.
 - Participant must have a subjective memory concern as reported by participant, study partner or clinician.
 - Abnormal memory function score on Wechsler Memory Scale ( adjusted for education ).
 - Mini-Mental State Exam ( MMSE ) score between 20 and 26 ( inclusive ).
 - Clinical Dementia Rating ( CDR ) = 0.5 or 1.0.
 - National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association ( NINCDS/ADRDA ) criteria for probable AD.
 - Stability of Permitted Medications for 4 weeks. In particular, participants may take :.
 - Antidepressants lacking significant anticholinergic side effects.
 - Estrogen replacement therapy.
 - Gingko biloba is permissible but discouraged.
 - Washout from psychoactive medication ( e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.
 - Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screening.
 Specific Inclusion Criteria for follow-up participants from ADNI1 and ADNI GO :.
 - Must have been enrolled and followed in ADNI1 for at least one year or enrolled in ADNI-GO with original diagnosis of Cognitively Normal ( CN ), Mild Cognitive Impairment ( MCI ) or Early Mild Cognitive Impairment ( EMCI ) regardless of whether a diagnostic conversion has occurred since initial enrollment in ADNI.
 - Willing and able to continue to participate in an ongoing longitudinal study. A reduced battery of tests is allowable if the participant is not able/willing to complete the full battery.
 - Study partner is available who has frequent contact with the participant ( e.g. an average of 10 hours per week or more ) and can accompany the participant to all clinic visits for the duration of the protocol.
 Exclusion Criteria :.
 General ( applies to each category ):.
 - Screening/baseline MRI scan with evidence of infection, infarction or other focal lesions; Participants with multiple lacunes or lacunes in a critical memory structure are excluded.
 - Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.
 - Major depression, bipolar disorder as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition ( DSM-IV ) within the past 1 year.
 - Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder.
 - History of schizophrenia.
 - History of alcohol or substance abuse or dependence within the past 2 years.
 - Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
 - Clinically significant abnormalities in B12 or TFTs that might interfere with the study.
 - Residence in skilled nursing facility.
 - Current use of specific psychoactive medications ( e.g.,certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.); Current use of warfarin or dabigatran ( exclusionary for lumbar puncture ).
 - Use of investigational agents one month prior to entry and for the duration of the trial.
 - Participation in clinical studies involving neuropsychological measures being collected more than one time per year.
 - Exclusion for FDG PET scan and amyloid imaging with Florbetapir F 18 : Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations ( CFR ) Title 21 Section 361.1.
 - Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the protocol director.
 Specific Exclusion Criteria for normal controls and SMC participants :.
 - Any significant neurologic disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
 Specific Exclusion Criteria for EMCI and LMCI participants :.
 - Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
 Specific Exclusion Criteria for AD participants :.
 - Any significant neurologic disease other than Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
 Specific Exclusion Criteria for follow-up participants from ADNI1 and ADNI GO :.
 - Participants will not be able to participate in FDG PET scan and amyloid imaging with Florbetapir F 18 if the following is true : Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations ( CFR ) Title 21 Section 361.1.
>>NCT02021682
Inclusion Criteria :.
 - Member of the Memory and Aging Project at Washington University.
 - Clinical Dementia Rating ( CDR ) and PET/ PIB scores.
 - Age 60 or greater.
 Exclusion Criteria :.
 - Clotting disorder.
 - Active anticoagulation therapy.
 - Active infection.
 - Meningitis.
 - Recent syncope.
 - Currently on experimental treatment targeting A or medications thought to influence A production or clearance rates ( benzodiazepines, muscarinic agents or anti-epileptics ).

>>NCT01825330
Inclusion Criteria :.
 1. Male or female age 60 - 90 years.
 2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSM-IV criteria.
 3. MMSE score 18 to 26.
 4. ADAS-Cog above 17.
 5. Physical clearance for study participation as evaluated by the clinician.
 6. Spouse, family member or professional caregiver agree and capable of taking care and be responsible for the participation of the patient in the study ( answering questions regarding the patient's condition and assuming responsibility for medication ).
 7. Agreement to participate in approximately 14 weeks during the study.
 8. Normal to near-normal vision and hearing with correction as needed ( e.g. corrective lenses, hearing aid ).
 9. Fluent in English or Hebrew.
 10. Minimum of 8th grade education.
 11. If medicated for AD, then use of cholinesterase inhibitors, memantine or Ginko-biloba for at least 3 months and on stable dose for at least 60 days prior to screening.
 Exclusion Criteria :.
 1. CDR 0, 0.5 or 3.
 2. Severe agitation.
 3. Mental retardation.
 4. Patient lacking capacity to consent to study participation.
 5. Unstable medical condition.
 6. Use of benzodiazepines or barbiturates 2 weeks prior to screening.
 7. Pharmacological immunosuppression.
 8. Participation in a clinical trial with any investigational agent within 6 months prior to study enrollment.
 9. History of Epileptic Seizures or Epilepsy.
 10. Contraindication for performing MRI scanning.
 11. Contraindication for receiving TMS treatment according to a TMS questionnaire.
 12. Pregnant women and women who have the ability to become pregnant unless they are on an acceptable method of contraception during the study.
 13. Patients with depression, bipolar disorder or psychotic disorders or any other neurological or psychiatric condition ( whether now or in the past ), which the Investigator finds as interfering with the study.
 14. Alcoholism or drug addiction as defined by DSM-IV within last 5 years ( addicted more than one year and or in remission less than 3 years ) or severe sleep deprivation.
 15. Patients with metal implants in the head, ( i.e. cochlear implants, implanted brain stimulators, aneurysm clips ) with the exception of metal implants in mouth.
 16. Patients with personal history of either any clinically defined medical disorder ( which the investigator finds as interfering with the study ) or any clinically defined neurological/psychiatric disorder ( other than AD ), including ( but not limited to ): epilepsy, stroke, brain lesions, substance abuse, vitamin B12 deficiency, abnormal thyroid function, cerebrovascular condition, other neurodegenerative disease, head trauma, multiple sclerosis; or personal history of previous neurosurgery or head trauma that resulted in loss of consciousness.
 17. Patients with any signs or symptoms of increased intracranial pressure, as determined in a neurological exam.
 18. Cardiac pacemakers.
 19. Implanted medication pumps.
 20. Intracardiac lines.
 21. Significant heart disease.
 22. Currently taking medication that lower the seizure threshold.
 23. Patients on which TMS Motor Threshold cannot be found.
 24. Patient underwent TMS treatment in the past.

>>NCT00951834
Inclusion Criteria :.
 - early stage of AD ( Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007 ).
 - age 60 - 100.
 - MMSE 20 - 26.
 - patient lives at home with at least one relative who perform external ratings/assessment.
 - co-medication with Donepezil ( Aricept, Pfizer Pharma GmbH ) with at least 3 months to maximum 6 months of existing stable medication.
 - maximum of 2 cups of black tea/die, no green tea, not more than > 500 ml/die of grapefruit juice.
 Exclusion Criteria :.
 - co-medication with NSAIDs ( longterm medication ) ( ASS is not an exclusion criteria ), Gingko- or other natural extracts, other anti-dementiva except of Donepezil.
 - familial autosomal-dominant inherited AD.
 - instable medical condition.
 - other primary psychiatric/neurologic disorders.
 - missing informed consent.
 - no readiness to save and refer pseudonym personal data.
 - hospitalisation due to juridical or legal regulation.
 - any condition disturbing or making MRI and other measures impossible.
 - clinically relevant GI-disorders at screening and 1 year before.
 - clinically relevant lung, infectious, heart or other CNS disorders, clinical or paraclinical suspicion of TBC, history of vascular CNS-disorders at screening and 1 year before.
 - clinically relevant liver disorders at screening and 1 year before.
 - clinically relevant functional disorders of liver, kidney or bone marrow defined by following lab values at screening :.
 - Marrow dysfunction :.
 - HB < 8.5 g/dl.
 - WBC < 2.5/nl.
 - Thrombocytes < 125/nl.
 - Kidney dysfunction :.
 - Creatinin-Clearance according to Cockcroft-Gault-Formula : Cl < 110ml/min ( male ) resp. Cl < 95ml/min ( female ), from the age of 30 decline of 10ml/min per decade.
 - Liver dysfunction :.
 - ASAT/ALAT > 3.5 x higher than the upper reference value.
 - Bilirubin > 2.0 mg/dl.
 - known allergy of elements of Sunphenon EGCg or additives of Sunphenon EGCg resp. placebo.
 - long-term hepatotoxic medication.
 - current intake of cytochrom P450 3A4 -inhibitors or -inductors, such as antimycotics of the azol-type or macrolide-antibiotics.
 - clinical-anamnestic or paraclinical manifestations suggesting an alcohol or drug abuse.
 - participation in any clinical trial < 3 months prior to screening or ongoing.
 - any medical, psychiatric or other condition which might constrain the ability of the patient to understand the informed consent, to give consent, to adhere to the protocol or to accomplish the study.
 - massive and extended sun exposure.
